Pasithea reports early PAS-004 trial data
Pasithea Therapeutics (NASDAQ:KTTA) reported positive interim Phase 1 clinical trial results for PAS-004, an oral MEK inhibitor being tested in advanced MAPK pathway-driven solid tumors, including patients previously treated with MEK and BRAF inhibitors.


_1430857_640x360_2505169987582-640x360.webp&w=3840&q=75)




_1430844_640x360_2505170499558-640x360.webp&w=3840&q=75)
_1430838_640x360_2505167939556-640x360.webp&w=3840&q=75)


